Connect your AI

Sutro Biopharma STRO Financing Cash Flow

Financing Cash Flow at other companies

PfizerPFE

-$2.86B+45.4%

Gilead SciencesGILD

-$4.24B-23.7%

RegenxbioRGNX

-$13.64M-135%

Nuvectis Pharma, Inc.NVCT

$7K-100.0%

XencorXNCR

$950K-23.9%

AnaptysBio, Inc.ANAB

$1.21M+104%

Other financials

Income statement

Revenue$14.5M-16.5%

Operating income-$29.7M+56.7%

Net income-$38.5M+49.3%

EPS (diluted)-$2.94+67.6%

Balance sheet

Cash & equivalents$73.7M-30.6%

Total debt$13.6M-36.3%

Total equity-$66.9M-159%

Total assets$242.0M-24.7%

Cash flow

Operating cash flow-$42.3M+37.7%

CapEx--100%

Free cash flow-$42.3M+37.8%

Valuation

Market cap$489.66M+624%

Enterprise value$429.61M-2,600%

P/S4.9×+3.9×

Profitability

Operating margin-120%-48.6pp

Net margin-154.2%-56.7pp

FCF margin-152.2%-51.1pp

Returns & leverage

Return on equity-234.2%—

Debt / equity0.5×+0.3×

Current ratio3.1×+1.0×

Where this comes from

Reported directly by Sutro Biopharma in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.

The official record: Sutro Biopharma’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Sutro Biopharma's financing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Sutro Biopharma's financing cash flow?: Sutro Biopharma (STRO) reported financing cash flow of $103.08M in Q1 2026.
How has Sutro Biopharma's financing cash flow changed year-over-year?: Sutro Biopharma's financing cash flow increased by 156074.2% year-over-year, from $66K to $103.08M.
What is the long-term trend for Sutro Biopharma's financing cash flow?: Over 2 years (2021 to 2024), Sutro Biopharma's financing cash flow has grown at a 434.3% compound annual growth rate (CAGR), from $3.3M to $94.08M.
What does financing cash flow mean?: Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.